{"id":"W2049420921","doi":"10.1007/s00192-013-2161-4","title":"What do we know and not know about mirabegron, a novel β3 agonist, in the treatment of overactive bladder?","year":2013,"lang":"en","type":"review","venue":"International Urogynecology Journal","topic":"Urinary Bladder and Prostate Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Mirabegron; Overactive bladder; Medicine; Tolterodine; Tolerability; Adverse effect; Solifenacin; Oxybutynin; Intensive care medicine; Urology; Internal medicine; Alternative medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006079153,0.0004324123,0.001352061,0.0006598915,0.000117644,0.0002179779,0.0004330587,0.000370935,0.001383638],"category_scores_gemma":[0.0001715429,0.0002571412,0.0004739191,0.0001805952,0.0003072865,0.0003356528,0.00008789054,0.001163614,0.00007890199],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005757075,"about_ca_system_score_gemma":0.0009102622,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003210894,"about_ca_topic_score_gemma":0.00004238124,"domain_scores_codex":[0.9971839,0.0004285098,0.0009652078,0.0004167215,0.0005719044,0.0004337964],"domain_scores_gemma":[0.9965448,0.001981826,0.0006130755,0.0002830698,0.0004007332,0.0001765159],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001756235,0.001440342,0.0001865522,0.0005497894,0.001713283,0.0006206095,0.001194089,6.614094e-7,0.000009165841,0.000215179,0.001288571,0.9926062],"study_design_scores_gemma":[0.002237563,0.002254097,0.001089701,0.004838697,0.0005838671,0.01036429,0.0004504427,0.00002253297,0.000006342868,0.0001932668,0.9777798,0.0001794061],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0009341546,0.9903567,0.0000119758,0.005087356,0.001162623,0.001208924,0.00008578441,0.000006233115,0.001146293],"genre_scores_gemma":[0.0002831595,0.9949557,0.0001858304,0.0001471826,0.0006070709,0.0002182243,0.00007177838,0.00004143899,0.003489656],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9924268,"threshold_uncertainty_score":0.9999881,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0678600327954524,"score_gpt":0.4015528724213044,"score_spread":0.333692839625852,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}